Myrtle Potter was President and Chief Operating Officer of Genentech, Inc. from 2000 to 2005. In this role, Potter helped steer the company through one of its most successful periods.
Genentech achieved record sales and earnings growth during each of the five years she led the
company and sales grew to over $5 billion.
Prior to Genentech, Potter was President of Bristol-Myers Squibb’s $4 billion, 3,500-person
U.S. Cardiovascular and Metabolic business. Potter began her biopharmaceutical career at Merck.
global life science advisory firm. Potter has dedicated over thirty years of service and leadership to America’s most successful global healthcare companies.
Potter was named to Fortune Magazine’s list of “Most Powerful Women in Business” on three